Latest News

View All >>

FDA Grants Accelerated Approval to Enhertu for Subgroup of Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

August 11th 2022

By Ryan McDonald

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

Use of Potentially Inappropriate Medications Associated With Increased Risks for Poor Outcomes in Older Patients With Cancer

August 11th 2022

By Brielle Benyon

The use of five or more medicines — as well as some drugs that could be deemed inappropriate — may put older patients with cancer at a higher risk for complications, such as weakness.

FDA Grants Tabrecta a Regular Approval for Certain Patients With Lung Cancer

August 11th 2022

By Brielle Benyon

The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.

Crying Over a Movie, Cancer and Lost Innocence

August 11th 2022

By Felicia Mitchell

“Love Story,” the story about a young woman who falls in love and then dies of cancer, affects me differently now than it did when I was a teenager and no experience with either love or cancer.

FDA Grants Priority Review to Investigational Drug for a Subtype of Advanced or Metastatic Breast Cancer

August 11th 2022

By Ryan McDonald

The FDA’s decision to grant the investigational drug elacestrant a priority review for patients with ER-positive, HER2-negative advanced or metastatic breast cancer was based on data that showed the treatment bested standard-of-care in terms of improving survival.